Cezol

Quick links to important sections

Cezol

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cezol

What is Cezol?

Cezol is a prescription medication belonging to a class of drugs known as cephalosporin antibiotics. Specifically, it is a first-generation cephalosporin designed to address various types of bacterial infections within the body.

Mechanism of Action

Cezol works by interfering with the way bacteria build their cell walls. A stable cell wall is essential for bacteria to survive and multiply in the human environment. By weakening this structure, the medication causes the bacterial cells to rupture and eventually die. Because this mechanism targets structures specific to bacteria, it does not affect human cells in the same manner.

Primary Uses

As an antibacterial agent, Cezol is effective only against infections caused by susceptible bacteria. It is commonly utilized in clinical settings to treat several types of conditions, including:

  • Respiratory tract infections: Targeting bacteria that affect the lungs and airways.
  • Skin and soft tissue infections: Addressing bacterial growth in skin layers or underlying tissues.
  • Urinary tract infections: Eliminating bacteria present in the renal system.
  • Bone and joint infections: Treating bacterial presence within the skeletal system.

It is important to note that Cezol, like all antibiotics, is intended for the treatment of bacterial infections only. It is not effective against viral infections, such as the common cold or the flu.

Regulatory References

  1. Cefazolin on the WHO Essential Medicines List

What side effects are possible with Cezol?

Possible side effects and safety information

The safety profile of Cefazolin (Cezol) is established through official regulatory documentation, which classifies potential adverse reactions by frequency and the body system affected. These regulatory summaries are based on data from clinical studies and post-marketing surveillance.

Adverse Reaction Scope

Classification Description (Based on Regulatory Documents)
Common Side Effects Gastrointestinal disturbances, such as diarrhoea and nausea, as well as localized pain, swelling, or redness at the injection site.
System-Organ Classes Officially documented effects are grouped into Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, Blood and Lymphatic System Disorders, and Nervous System Disorders.
Serious Adverse Reactions The label documents the potential for rare but serious reactions, including anaphylaxis (a severe allergic reaction), seizures (particularly at high doses or in patients with renal impairment), and severe gastrointestinal conditions like Clostridioides difficile-associated diarrhoea (CDAD).

Safety Considerations

The official safety information includes specific notes regarding its use in certain populations. Patients with pre-existing renal impairment carry an increased risk for central nervous system toxicity, which necessitates close monitoring. Furthermore, the label notes a documented risk of cross-hypersensitivity in individuals with a history of allergy to other beta-lactam antibiotics, such as penicillin. Cefazolin is formally contraindicated in patients with a known severe immediate hypersensitivity to cefazolin or the cephalosporin class of antibacterial drugs. The documentation also notes that diarrhoea, a common effect, may occur during treatment or persist for up to two months after stopping therapy.

This structure ensures the potential risks of the medicine are clearly communicated, defining the formal boundaries and constraints of its approved safety profile.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the overdose profile of Cezol (Cefazolin) by the risk of severe neurological manifestations associated with excessive drug levels in the bloodstream.

Category Official Regulatory Documentation
Documented overdose presentations Central Nervous System (CNS) excitation, specifically seizures and convulsions.
Population-specific overdose notes Increased risk of toxicity, including seizures, in patients with impaired renal function when the dosage is not appropriately adjusted.
When immediate medical help is required Seek immediate medical attention if the victim has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Overdose Management and Elimination

Official overdose statements:

  • The primary toxic manifestation documented in association with Cefazolin overdose is Central Nervous System (CNS) excitation, including seizures.
  • The risk of these toxic reactions is heightened in patients with impaired renal function due to reduced drug clearance, leading to inappropriately high serum concentrations.
  • Management of an overdose relies on symptomatic and supportive therapy.
  • Hemodialysis is documented as a measure that may be helpful in removing Cefazolin from the blood.
  • No specific antidote is known for Cefazolin overdose.
  • Individuals are instructed to seek immediate medical attention and contact Poison Control for advice for severe signs such as collapse or seizure.

Connection to the overall overdose profile: Regulatory documents define the Cefazolin overdose profile primarily by the risk of seizures resulting from excessively high concentrations, particularly in patients with impaired kidney function. This serious outcome mandates seeking immediate medical attention when neurological events occur. The documented management protocol is non-specific, relying on supportive care and the procedure of hemodialysis to aid drug elimination.

Therapeutic Uses of Cezol

What Cezol Treats: Main Uses and Benefits

Cezol (Cefazolin) is commonly used to address moderate to severe bacterial infections that have become systemic, such as septicemia or established infections in the bone, joints, and heart lining. This medication may be part of symptomatic management for certain serious infections caused by bacteria. The medication is applied to address the conditions marked by the underlying bacterial presence, which assists with managing the advancement of acute manifestations and **supports vital function stability during periods of heightened systemic burden.


The medication is used in addressing focal infections in areas like the skin and soft tissues, including complex burn or wound infections, as well as certain infections in the respiratory and urinary tracts. In these contexts, the medication is relevant for easing the painful and disruptive local inflammatory symptoms—such as redness, swelling, and severe pain—that interfere with the patient's immediate comfort and stability.

A primary clinical role for Cefazolin is providing perioperative prophylaxis to patients undergoing high-risk procedures, including major orthopedic or cardiac surgery. This preventative use is applied to help reduce the risk of developing a postoperative infection (surgical site infection), which supports management of the infection risk associated with the procedure and contributes to improved day-to-day comfort and stability during the recovery phase.

“It is commonly used when short-term symptomatic assistance is needed in clinical settings that involve acute or disruptive symptom patterns.”

Quick Fact: Use in Acute Symptomatic Periods
Cefazolin is commonly used across conditions presenting with acute episodes where symptoms related to systemic imbalance and inflammatory states require supportive management to help ease the overall symptom burden.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Cezol (Cefazolin) eligibility is strictly defined by regulatory documents, outlining populations who can and cannot use the medicine.

Absolute Contraindications

Use of Cezol is contraindicated in patients with a history of immediate hypersensitivity to Cefazolin, any cephalosporin antibacterial drug, or other beta-lactam antibiotics, including penicillins. This prohibition is due to the documented risk of cross-hypersensitivity.


Age and Condition-Based Restrictions

The medicine is approved for adults and pediatric patients generally one month of age and older. Use is not established for premature infants and infants under one month of age.

Eligibility is restricted for patients with impaired renal function. To avoid drug accumulation and potential central nervous system toxicity, these individuals require a lower daily dosage or extended dosing intervals.

Use during pregnancy and lactation is conditional, permitted only if considered clearly necessary. Regulatory guidance also advises caution for patients with a history of gastrointestinal disease, particularly colitis.

What should I know about interactions with other medicines?

Cezol Interactions with other medicines and products

The official interaction profile for Cezol (Cefazolin) is defined by specific regulatory constraints concerning pharmacokinetics, pharmacodynamics, and procedural testing. These restrictions are based solely on information documented in government regulatory labeling.


Pharmacokinetic Interactions and Administration Restrictions

The co-administration of Cefazolin with Probenecid is not recommended due to a defined pharmacokinetic interaction. Probenecid acts to inhibit the renal tubular secretion of Cefazolin, a documented mechanism of clearance reduction. This interference leads to a regulatory outcome of increased and more prolonged Cefazolin blood levels. The official profile does not specify interactions mediated by cytochrome P450 enzymes.


Pharmacodynamic Effects and Contextual Cautions

A pharmacodynamic interaction is noted with anticoagulant agents, as Cefazolin use may be associated with a fall in prothrombin activity. For individuals with impaired renal function, cautions apply when Cefazolin is co-administered with nephrotoxic agents, such as Aminoglycoside antibiotics. This note addresses the increased risk due to Cefazolin’s primary dependence on renal excretion. Furthermore, Cefazolin may cause a false positive reaction for glucose in the urine when tested with non-enzyme-based solutions, requiring specific procedural awareness. No mandatory timing separations or documented interactions with food, alcohol, or herbal products are listed in primary regulatory labels.

Mechanism of Action

Cezol (Cefazolin) exerts its action by disrupting the structural integrity of susceptible bacteria, leading to cell death.

Blocking the Final Step of Bacterial Cell Wall Assembly

Cefazolin functions as an irreversible inhibitor of key bacterial enzymes known as Penicillin-Binding Proteins (PBPs). These transpeptidases are essential for forming the rigid, complex structure of the bacterial cell wall. By covalently and permanently binding to the PBPs, the drug immediately halts the critical cross-linking step in the peptidoglycan synthesis pathway.

Triggering Cell Autodestruction and Lysis

The inability to form a structurally sound cell wall initiates a mechanistic cascade. The damaged wall structure leads to the dysregulated activation of the bacteria's own degradative enzymes, autolysins. The resulting unstable cell, unable to withstand internal osmotic pressure, rapidly ruptures (lysis). This sequence results in the bactericidal action which causes the elimination of the susceptible bacterial population.

Mechanistic Limitation by beta-Lactamase

The mechanism is constrained by bacterial resistance mechanisms, primarily the production of beta-lactamase enzymes. These enzymes nullify the drug's activity by hydrolyzing and cleaving the beta-lactam ring structure essential for PBP binding, thereby preventing the initial inhibitory step from occurring, as the drug molecule is rendered inactive.

Dosage and Administration Information

How to Use Cezol (Cefazolin): Administration Guidelines

Cezol (Cefazolin) is administered exclusively through parenteral routes, primarily via intravenous (IV) injection or infusion or intramuscular (IM) injection, requiring a supervised clinical setting for proper handling. The medicine is commonly supplied as a lyophilized powder that must be reconstituted and diluted prior to use. For IV use, the solution is typically infused over 30 minutes, while a direct IV injection must be administered slowly over a period of three to five minutes.

Standard adult dosing ranges from 250 mg to 1.5 grams per dose, with frequency generally set at intervals of every 6, 8, or 12 hours, depending on the clinical scenario. A major use pattern involves perioperative prophylaxis, where a dose of 1 to 2 grams is administered 1/2 to 1 hour before surgery, and often continued for 24 hours post-procedure, or extended to three to five days for certain high-risk surgeries.

Specific dose adjustments are required for patients with renal impairment (reduced kidney function), involving an extension of the dosing interval or a reduction in the subsequent dose when creatinine clearance is low. In pediatric patients, the total daily dose is calculated based on body weight, typically ranging from 25 to 100 mg per kg, divided into three or four equal doses. These guidelines describe the mechanical use of Cefazolin.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cezol

The research evidence for Cezol (Cefazolin) is drawn from decades of study, primarily focusing on its use in hospital settings to address or prevent bacterial infections. Regulatory bodies rely on these findings, which consist of various research methods including randomized controlled trials (RCTs), systematic reviews, and large observational studies. This overview describes the structure of that evidence without providing clinical advice or treatment recommendations.


Evidence for use in Preventing Infection During Surgery (Perioperative Prophylaxis)

Research regarding the use of Cezol before certain surgeries includes numerous randomized controlled trials (RCTs) and comprehensive meta-analyses that explored the measured outcomes for patients who received Cefazolin against those who received a different antibiotic or a non-treatment control. Researchers focused on measured outcomes such as the rate of surgical site infection (SSI) occurrence, typically tracked for 30 to 90 days after the procedure. The evidence from this research provides context for clinical practices regarding short-term anti-infective administration in the context of procedures like major orthopedic or cardiac surgery. Studies also report on pharmacokinetic measurements, which track the drug concentration in the body during the operation, contributing to understanding the drug's concentration patterns.


Evidence for use in Treating Serious Blood and Systemic Infections

Research into Cefazolin's use for severe systemic infections, such as those caused by susceptible Staphylococcus aureus (MSSA bacteremia), involves many systematic reviews and large observational cohort studies. These studies monitored outcomes such as all-cause mortality at 30 and 90 days and the rate of infection relapse over time. Studies have reported measurements of patient outcomes when Cefazolin was used. Researchers generally acknowledge that this body of evidence remains largely observational and non-randomized. This means that an unaddressed question remains concerning Randomized Controlled Trials (RCTs) designed to compare these specific treatment options.


Evidence for use in Addressing Bone and Joint Infections

Research exploring outcomes related to Cefazolin in chronic conditions like osteomyelitis (bone infection) and septic arthritis (joint infection) is primarily based on retrospective observational studies and long-term case analyses. Researchers have focused on long-term follow-up—often tracking patients for two or more years—to measure clinical outcomes, including the absence of infection signs and the frequency of recurrence. However, because the evidence is largely non-randomized, there is limited data to establish a direct causal effect for Cefazolin alone, separate from other interventions, and can only describe observed patterns, not outcomes established through randomization.

Key Studies & References

  1. Cefazolin Injection: MedlinePlus Drug Information (for approved indications and context)
  2. SHC Surgical Antimicrobial Prophylaxis Guideline (used for context on dosing/specific populations)

Frequently Asked Questions (FAQ)

Common questions about Cezol (FAQ)


Q: How quickly should I expect Cezol to start having an effect?

Official patient information indicates that observed clinical improvement typically begins within the first few days of starting treatment for susceptible infections. The full benefit of the medication depends on the specific condition being treated.

Q: Does Cezol interact negatively with common pain relievers like ibuprofen or acetaminophen?

Regulatory interaction data describes that Cefazolin may decrease the rate at which the body excretes acetaminophen. This potential change in drug handling could potentially result in higher levels of acetaminophen remaining in the body. Official regulatory documents do not list a major interaction concerning common over-the-counter anti-inflammatories like ibuprofen.

Q: Does taking Cezol make people feel excessively sleepy or tired?

Adverse reaction reports include occurrences of drowsiness, tiredness, and weakness (sometimes referred to as asthenia). Changes in energy or alertness are factors that may be discussed with a healthcare provider.

Q: What are the official guidelines regarding the long-term use of Cezol?

Official precautions indicate that prolonged use may result in the overgrowth of non-susceptible organisms. Regulatory documents also associate long-term treatment with possible changes in the International Normalized Ratio (INR), which is a measure of blood clotting.

Q: Can Cezol affect my ability to drive or operate machinery?

Official product information states that adverse reactions affecting the nervous system have been reported. These effects may include confusion and dizziness, which are factors that can impair the mental alertness required for tasks like driving or operating machinery.

Q: What signs or symptoms might indicate a serious allergic reaction to Cezol?

Serious allergic reactions, called anaphylaxis, are rare but documented in official warnings. Symptoms that might signal a serious reaction include itching, hives, hoarseness, trouble breathing or swallowing, or swelling of the hands, face, or mouth.

Q: Does Cezol interact with common vitamins, herbs, or dietary supplements?

The official regulatory documents list specific, significant drug-to-drug interactions. While major interactions with most non-prescription supplements or foods are not typically noted, minor interactions with some herbal products or specific vitamins may be documented in certain drug interaction reports.

Q: What is the typical course or length of treatment prescribed for Cezol?

The course of treatment with Cezol is determined by the specific infection being treated. Official guidelines indicate that the standard course for many bacterial infections, like those affecting skin and soft tissue, is often reported to be 7 to 14 days.

Q: Can Cezol cause changes in mood or anxiety levels?

Adverse event reports include effects related to the central nervous system. These effects are sometimes described as including confusion and restlessness.

Q: Does Cezol cause changes in appetite, such as weight gain or weight loss?

Adverse reaction reports include changes in appetite. Specifically, loss of appetite (anorexia), as well as both weight gain and unusual weight loss have been reported as adverse reactions.

Q: Is Cezol safe to use for people who have documented liver problems?

Official regulatory documents list liver disease as a pre-existing medical problem that requires caution when using the medicine. The inclusion of this caution is based on regulatory assessment of how the medicine is processed by the body.

Q: How long does it take for Cezol to be completely eliminated from the body?

Official product information contains data on how the drug is handled by the body. Following intravenous administration, the serum half-life for the drug—the time it takes for half of the drug to be eliminated—is reported to be approximately 1.8 hours.

Q: Are the side effects of Cezol usually permanent or do they go away after stopping the medication?

Official reports describe most common side effects, such as nausea and vomiting, as typically resolving during or after the period of therapy. However, official safety documentation notes that one common effect, diarrhea, has been reported to persist for up to two months after treatment is stopped.

Q: What is the difference between the brand name and generic versions of Cezol?

Cezol is a trade name for the active ingredient Cefazolin. Regulatory agencies require that a generic product containing the same active ingredient is bioequivalent to the brand-name product. This means the generic product must be qualitatively and quantitatively the same as the reference drug.

How should Cezol be stored and disposed of?

Cezol (Cefazolin) requires specific storage conditions based on its formulation.


Storage Conditions

Powder and Solution Storage

Formulation Required Storage Condition Stability Limit
Unreconstituted Powder Controlled Room Temperature (20 C to 25 C), protected from moisture and light. Original shelf-life
Frozen Premixed Solution Freezer (le -20 C). Thawed solution stable up to 30 days refrigerated.
Reconstituted Solution Refrigeration (2 C to 8 C). Up to 3 days (manufacturer dependent).

Essential Handling and Safety

Containers must be kept tightly closed. After thawing, the solution must not be refrozen, and any solution that appears cloudy or has precipitate must be discarded. The medication must be kept out of the reach of children at all times.


Disposal Instructions

Unused or expired product and any unused portions of the reconstituted solution must be discarded. Disposal of the medication and its containers must be performed in accordance with local and national regulations to ensure proper environmental handling and prevent unauthorized access.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cezol found in:

A-Z Index: